OpenAlex
PricingAboutJobs
Log inGet started
Work

Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease

HTML

Year: 2003
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Amyloid
DOI: 10.3109/13506120308995249
Authors: Christoph Hock, Alessia Maddalena, Andreas Raschig, Franz Müller-Spahn, Gerhard Eschweiler, Klaus Huger, Isabella Hewer, Harald Hampel, Thomas Müller-Thornsen, Wolfgang Oertel, Marion Wienrich, Andri Signorell, Charo Gonzalez-agosti, Roger M. Nitsch
Institutions: University of Zurich, Boehringer Ingelheim (Germany), University of Basel, University of Tübingen, Freie Universität Berlin, Ludwig-Maximilians-Universität München, Universität Hamburg, University Medical Center Hamburg-Eppendorf, Philipps University of Marburg
Language: English

Topic: Alzheimer's disease research and treatments
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: muscarinic M1 receptor agonist, Alzheimer's disease, amyloid-beta 42, Aβ40, cerebrospinal fluid biomarkers, alpha-secretase, APP processing, non-amyloidogenic pathway
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W1971834278
FWCI: 2.304
Cites: 25
Cited by: 119
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security